Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05722873 · ClinicalTrials.gov registry record · NA
The Metabolic Effects of Intermittent Fasting
A NA study of Normal and Overweight Individuals at High-risk of Diabetes, sponsored by University of Pittsburgh.
- Recruiting
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT05722873: Recruiting NA study of Normal and Overweight Individuals at High-risk of Diabetes, sponsored by University of Pittsburgh.
NCT05722873 is a NA study of Normal and Overweight Individuals at High-risk of Diabetes that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05722873, a NA study of Normal and Overweight Individuals at High-risk of Diabetes, is actively recruiting participants, sponsored by University of Pittsburgh.
- RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
Caloric restriction has beneficial metabolic effects in humans including weight loss and improvement in blood pressure and lipid levels. Intermittent fasting has emerged as a popular alternative to caloric restriction as it does not require daily adherence to a dietary protocol, but whether the benefits of fasting protocols are dependent on weight loss is not known. In this study, the investigators will explore the metabolic effects of fasting and evaluate whether these effects, including negative effects on bone metabolism, are independent of weight loss.
Primary Outcome
Change in triglyceride carbon content and degree of saturation (% variation explained by both carbon number and double bond number in a regression model) between Baseline and Final Intervention visits
Conditions Studied
Interventions
- BEHAVIORAL Fasting arm
- BEHAVIORAL Weight maintenance
- BEHAVIORAL Counseling
Study Locations (1)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-10-25 |
| Est. Completion | 2028-06-30 |
| Phase | NA |
What NCT05722873 shows while recruiting
NCT05722873 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Normal and Overweight Individuals at High-risk of Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Fasting arm is the first listed.
NCT05722873 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05722873 about?
NCT05722873 is a clinical study titled "The Metabolic Effects of Intermittent Fasting". Caloric restriction has beneficial metabolic effects in humans including weight loss and improvement in blood pressure and lipid levels. Intermittent fasting has emerged as a popular alternative to caloric restriction as it does not require daily adherence to a dietary protocol, but whether the bene...
What is the current status of trial NCT05722873?
This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2023-10-25. Estimated completion is 2028-06-30.
What conditions does trial NCT05722873 study?
This clinical trial studies the following conditions: Normal and Overweight Individuals at High-risk of Diabetes.
What interventions are being tested in trial NCT05722873?
The interventions under investigation include: Fasting arm (BEHAVIORAL), Weight maintenance (BEHAVIORAL), Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT05722873?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05722873 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05722873's enrollment target sits among peer trials
90 942nd of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI